BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22894087)

  • 1. [Diabetes treatment with the aim of blood glucose normalization].
    Hoizumi M; Yamada Y
    Nihon Rinsho; 2012 Aug; 70(8):1445-50. PubMed ID: 22894087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Present condition and future prospects in diagnosis of and therapy for diabetes mellitus].
    Seino Y
    Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):713-6. PubMed ID: 19469089
    [No Abstract]   [Full Text] [Related]  

  • 3. The alpha-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic beta-cells in OLETF rats.
    Fukaya N; Mochizuki K; Tanaka Y; Kumazawa T; Jiuxin Z; Fuchigami M; Goda T
    Eur J Pharmacol; 2009 Dec; 624(1-3):51-7. PubMed ID: 19818342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term consumption of fermented soybean-derived Chungkookjang enhances insulinotropic action unlike soybeans in 90% pancreatectomized diabetic rats.
    Kwon DY; Jang JS; Hong SM; Lee JE; Sung SR; Park HR; Park S
    Eur J Nutr; 2007 Feb; 46(1):44-52. PubMed ID: 17200876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Goal and index of management in diabetes mellitus].
    Toyota T
    Nihon Rinsho; 1997 Nov; 55 Suppl():28-33. PubMed ID: 9434438
    [No Abstract]   [Full Text] [Related]  

  • 6. Type II diabetes mellitus.
    Edelman SV
    Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Voglibose].
    Hara T; Hotta N
    Nihon Rinsho; 1997 Nov; 55 Suppl():114-9. PubMed ID: 9434453
    [No Abstract]   [Full Text] [Related]  

  • 8. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Achieving better control of blood sugar--understanding of oral hypoglycemic agents according to their characteristics in pharmacological action mechanism (discussion)].
    Kawamori R; Kadowaki T; Ishida H
    Nihon Rinsho; 2004 Apr; 62(4):831-9. PubMed ID: 15106356
    [No Abstract]   [Full Text] [Related]  

  • 10. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Insulin pump in type 2 diabetes: B-cell focused treatment].
    Picková K; Rušavý Z
    Vnitr Lek; 2017; 63(6):441-445. PubMed ID: 28840741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oral therapy of diabetes].
    Presse Med (1893); 1969 Jun; 77(31):1117-20. PubMed ID: 5793543
    [No Abstract]   [Full Text] [Related]  

  • 13. [Management of diabetes in the elderly].
    Ikegami H
    Nihon Ronen Igakkai Zasshi; 2006 May; 43(3):265-73. PubMed ID: 16813072
    [No Abstract]   [Full Text] [Related]  

  • 14. The antidiabetic effect of Geigeria alata is mediated by enhanced insulin secretion, modulation of β-cell function, and improvement of antioxidant activity in streptozotocin-induced diabetic rats.
    Hafizur RM; Babiker R; Yagi S; Chishti S; Kabir N; Choudhary MI
    J Endocrinol; 2012 Sep; 214(3):329-35. PubMed ID: 22736483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved glycemic control enhances the incretin effect in patients with type 2 diabetes.
    An Z; Prigeon RL; D'Alessio DA
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4702-8. PubMed ID: 24092826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Diabetic Activities of Gastrodia elata Blume Water Extracts Are Mediated Mainly by Potentiating Glucose-Stimulated Insulin Secretion and Increasing β-Cell Mass in Non-Obese Type 2 Diabetic Animals.
    Yang HJ; Kim MJ; Kwon DY; Kim DS; Lee YH; Kim JE; Park S
    Nutrients; 2016 Mar; 8(3):161. PubMed ID: 26978400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapies for newly-onset diabetic patients].
    Kawamori R
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():525-32. PubMed ID: 15779435
    [No Abstract]   [Full Text] [Related]  

  • 18. Protection of pancreatic beta-cells: is it feasible?
    Bonora E
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salicylates as hypoglycemic agents.
    Baron SH
    Diabetes Care; 1982; 5(1):64-71. PubMed ID: 6754304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.